DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.

Employees

108

Sector

Pharmaceuticals

Calendar

05/03/2025 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
21/01/25	0.9100 €	-1.09%	290,016
20/01/25	0.9200 €	+2.22%	434,109
17/01/25	0.9000 €	-1.32%	329,001
16/01/25	0.9120 €	+4.71%	1,251,102
15/01/25	0.8710 €	-1.02%	1,377,041

Real-time Euronext Paris, January 21, 2025 at 11:40 am

More quotes

Income Statement and Estimates

income-statement-evolution-chart DBV-TECHNOLOGIES

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.9200EUR

Average target price

2.460EUR

Spread / Average Target

+167.39%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart DBV-TECHNOLOGIES

Company calendar

Real-time Euronext Paris Other stock markets 11:40:53 21/01/2025 GMT			5-day change	1st Jan Change
0.9100 ^EUR	-1.09%		+3.41%	+44.44%

01-15	European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading	MT
01-14	European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	MT

Capitalization	94.35M 98.11M 89.07M 79.77M 140M 8.46B 157M 1.08B 401M 3.49B 368M 360M 15.27B	P/E ratio 2024 *	-0.71x	P/E ratio 2025 *	-0.68x
Enterprise value	-54.42M -56.6M -51.38M -46.01M -81.04M -4.88B -90.38M -624M -231M -2.01B -212M -208M -8.81B	EV / Sales 2024 *	-11.9x	EV / Sales 2025 *	11.2x
Free-Float	98.83%	Yield 2024 *	-	Yield 2025 *	-

European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading	01-15	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	01-14	MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading	01-13	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	01-10	MT
DBV Technologies: positive follow-up data for EPITOPE	01-09	CF
DBV Technologies S.A. - Special Call	01-08
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading	01-08	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Flat for Week	01-03	MT
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	12-31	MT
European Equities Traded in US as American Depositary Receipts Tread Water Friday, Up 3% for Week	12-27	MT
European Equities Traded in the US as American Depositary Edge Higher in Thursday Trading	12-26	MT
European Equities Traded in the US as American Depositary Move Slightly Lower in Thursday Trading	12-19	MT
European Equities Traded in the US as American Depositary Rise in Wednesday Trading	12-18	MT

Goldman Sachs Adjusts Price Target on DBV Technologies to $1 From $1.30, Keeps Sell Rating	02/11/23	MT
Kepler Cheuvreux Upgrades DBV Technologies to Buy From Hold	03/08/22	MT
Goldman Sachs Downgrades DBV Technologies to Neutral From Buy	10/05/22	MT
JMP Securities Adjusts Price Target on DBV Technologies to $5 From $8, Maintains Market Outperform Rating	21/12/21	MT
HC Wainwright Adjusts DBV Technologies' Price Target to $10 From $14, Keeps Buy Rating	21/12/21	MT

DBV Technologies Share Price

Equities

DBV

FR0010417345

Pharmaceuticals

Valuation: DBV Technologies

Chart: DBV Technologies

Latest news: DBV Technologies

Last Transcript: DBV Technologies

Analysts' recommendations: DBV Technologies

Press Releases: DBV Technologies

News in other languages: DBV Technologies

Quotes and Performance

Course Extremes

Managers and Directors: DBV Technologies

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF	01-13	GL
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF	01-13	AQ
DBV Technologies : Announces Positive 3 Year Results from EPITOPE Phase 3 Open Label Extension Study	01-08	PU
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study	01-08	GL
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study	01-08	AQ

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF	01-13
DBV Technologies : plus forte hausse du marché SRD à la mi-séance du lundi 13 janvier 2025	01-13
DBV Technologies : plus forte baisse du SRD à la clôture du vendredi 10 janvier 2025	01-10
DBV Technologies : plus forte baisse du SRD à la mi-séance du vendredi 10 janvier 2025-	01-10
DBV Technologies : plus forte hausse du marché SRD à la clôture du jeudi 9 janvier 2025	01-09

1 day	-1.09%
1 week	+3.41%
Current month	+44.44%
1 month	+45.14%
3 months	+26.74%
6 months	+1.68%
Current year	+44.44%

Director	Title	Age	Since
Daniel Tassé CEO	Chief Executive Officer	65	28/11/2018
Virginie Simone Jeanine Verrechia DFI	Director of Finance/CFO	55	05/11/2023
Kevin P. Malobisky COO	Chief Operating Officer	-	30/11/2023

Manager	Title	Age	Since
Don Soland BRD	Director/Board Member	66	05/03/2015
Michael Goller BRD	Director/Board Member	50	20/10/2015
Maïlys Ferrère BRD	Director/Board Member	61	20/06/2016

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
DBV TECHNOLOGIES	-1.09%	+3.41%	-46.56%	-68.20%	98.11M
MERCK KGAA	+0.35%	+1.21%	-3.65%	-26.35%	64.2B
KYOWA KIRIN CO. LTD.	-0.44%	-1.97%	-3.36%	-21.67%	7.5B
HALOZYME THERAPEUTICS, INC.	-1.03%	+1.22%	+60.47%	+63.29%	6.97B
YUHAN CORPORATION	-2.09%	-4.72%	+119.77%	+142.29%	6.83B
SK BIOPHARMACEUTICALS CO., LTD.	-0.91%	-5.64%	+22.69%	+26.40%	5.92B
BETTA PHARMACEUTICALS CO., LTD.	-0.09%	+6.60%	+27.83%	-21.43%	3.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+2.09%	+5.21%	+30.66%	+21.96%	2.15B
SUPERNUS PHARMACEUTICALS, INC.	-0.34%	+0.45%	+36.39%	+29.16%	2.08B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+2.19%	-0.18%	-35.41%	+13.84%	1.71B
Average	-0.14%	+0.84%	+20.88%	+15.93%	10.07B
Weighted average by Cap.	-0.01%	+0.95%	+12.71%	-2.27%

	2024 *	2025 *
Net sales	4.59M 4.78M 4.34M 3.88M 6.84M 412M 7.63M 52.67M 19.52M 170M 17.91M 17.54M 743M	4.66M 4.85M 4.4M 3.94M 6.94M 418M 7.74M 53.47M 19.81M 172M 18.18M 17.81M 755M
Net income	-121M -126M -114M -102M -180M -10.83B -201M -1.39B -514M -4.47B -471M -462M -19.56B	-110M -115M -104M -93.23M -164M -9.89B -183M -1.26B -469M -4.08B -430M -421M -17.85B
Net Debt	-149M -155M -140M -126M -222M -13.34B -247M -1.71B -632M -5.5B -580M -568M -24.08B	-42.29M -43.98M -39.93M -35.76M -62.98M -3.79B -70.24M -485M -180M -1.56B -165M -162M -6.85B